Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chromos Molecular Systems has entered into a cell line engineering service agreement with Genitope Corporation to develop a cell line using its ACE System for manufacture of a biopharmaceutical product.
Subscribe to our email newsletter
Under the agreement, Chromos will engineer cell lines for the expression of a monoclonal antibody for Genitope using the ACE System. The financial details of the agreement were not disclosed.
Chromos’ ACE System is a biological engineering system based on artificial chromosome technology that facilitates the rapid engineering of stable high expressing production cell lines for the clinical and commercial manufacture of biopharmaceuticals.
Recent data has shown that cell lines engineered by Chromos using the ACE System are capable of achieving monoclonal antibody yields of greater than 4g/L in a non-optimized bioreactor system, a four-fold improvement over the partner’s original cell line. Chromos has also used an ACE System-derived cell line to manufacture its lead product, CHR-1103.
Chromos also believes the versatility of the ACE System also enables the rapid generation of research grade material to support preclinical research programs along with the ability to incorporate multiple genes into a production cell line. This could provide cost savings in the production of biopharmaceuticals.
The ACE System is Chromos’ leading revenue generator and is licensed non-exclusively to Pfizer, Centocor and Cambridge Antibody Technology.